INDIANAPOLIS, Jan. 30, 2020 /PRNewswire/ — Concentrics Research (Indianapolis, IN and Parsippany, NJ) and STATKING Clinical Services (Fairfield, OH) have formed a Joint Venture to provide contract research organization (CRO) services including data management and statistical services.
“This formalizes a partnership that has existed for many years; it extends Concentrics’ in-house services for clinical data management and statistical services,” stated Julie Aker, President & CEO of Concentrics. “We are delighted to expand our process integration and consultative services since our research studies have all become more challenging and complex! STATKING offers comprehensive statistical design, programming and analysis capabilities to complement Concentrics’ CRO services.”
“This JV incorporates Concentrics’ infrastructure for quality assurance and information technology into STATKING’s services to facilitate regulatory compliance and audit readiness,” said Dennis King, STATKING President and CEO, “we are proud of our accomplishment to formalize this partnership.”
Concentrics offers CRO services for late-stage studies (Phase II-IV, Rx-to-OTC Switch, consumer and device studies) including research design and execution expertise for pharmaceutical and device companies. Services include study design, protocol development, recruitment, IRB submission, monitoring, data collection and medical writing. Concentrics’ staff includes research, medical, quality, information technology and telemedicine services. For more information, visit www.concentricsresearch.com.
STATKING Clinical Services provides biostatistics and clinical data management for clinical trials for the regulatory approval of novel drug and medical device products. For more information, visit www.statkingclinical.com.
Contact Information:
Concentrics Research
Julie Aker, President & CEO
julie.aker@concentricsresearch.com
View original content:http://www.prnewswire.com/news-releases/concentrics-research-announces-joint-venture-with-statking-clinical-services-300996585.html
SOURCE Concentrics Research
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…